research Special Focus Issue: Transdermal, Topical and Folicular Drug Delivery Systems
New drug delivery systems improve treatment effectiveness and patient experience.
Search
for
Sort by
Research
450-480 / 1000+ results research Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research Oral isotretinoin combined with topical clobetasol 0.05% and tacrolimus 0.1% for the treatment of frontal fibrosing alopecia: a randomized controlled trial
Taking oral isotretinoin with creams worked better for treating a type of hair loss than creams alone.
research Treatment Survival and Reasons for Discontinuation in Patients with Recalcitrant Folliculitis Decalvans
Effective immunomodulatory treatments and a personalized approach are crucial for managing severe folliculitis decalvans.
research 5α-Reductase inhibitors, antiviral and anti-tumor activities of some steroidal cyanopyridinone derivatives
Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
research 90 Exploring the therapeutic potential of DHODH inhibitor farudodstat for alopecia areata treatment in a novel ex vivo model of human hair follicle immune privilege collapse
Farudodstat may effectively treat alopecia areata without harming hair follicles.
research Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Finasteride.
research Enhanced Insights into Frontal Fibrosing Alopecia: Advancements in Pathogenesis Understanding and Management Strategies
Frontal Fibrosing Alopecia needs better diagnostics and treatments, with dutasteride showing promise.
research Baseline methotrexate does not impact the incidence of infliximab infusion reactions: Results from a Canadian real-world treatment registry
Clofazimine effectively treated ashy dermatosis in a patient.
research Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
Afatinib often causes skin problems that need proactive management.
research Successful treatment of female-pattern hair loss with spironolactone in a 9-year-old girl
Spironolactone successfully treated hair loss in a 9-year-old girl.
research FACILE WATER MEDIATED SYNTHESIS OF FINASTERIDE FORM-I, AN AZAANDROSTANE STEROID
A simple and eco-friendly method was developed to make finasteride Form-I using water.
research Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double‐blind placebo‐controlled trial
The new clobetasol propionate foam is effective and safe for treating alopecia areata.
research Folliculitis decalvans responsive to tofacitinib: A case series
Tofacitinib may effectively treat folliculitis decalvans.
research Topical finasteride beneficial in androgenic alopecia
Rubbing finasteride on the scalp helps with hair loss.
research Anti‐Fertility Effects of Amlodipine in Adult Male Wistar Rats
Amlodipine impairs fertility in male rats by affecting sperm and testicular structure.
research FORMULATION AND EVALUATION OF A TOPICAL GEL CONTAINING MINOXIDIL AND TOFACITINIB CITRATE FOR ALOPECIA AREATA
The formulated gel is a promising treatment for alopecia areata.
research A 5α-reductase inhibitor, finasteride, increases differentiation and proliferation of embryonal carcinoma cell-derived-neural cells
research Synthesis and Evaluation of 2‘-Substituted 4-(4‘-Carboxy- or 4‘-carboxymethylbenzylidene)-N-acylpiperidines: Highly Potent and in Vivo Active Steroid 5α-Reductase Type 2 Inhibitors
Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
research Patient Considerations when Using Ritlecitinib for Alopecia Areata in Adolescents: Guidance for the Clinicians
Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
research Attenuation of disease process following treatment with low-dose naltrexone in patients with frontal fibrosing alopecia and lichen planopilaris: A retrospective study
Low-dose naltrexone helps improve symptoms and stabilize frontal fibrosing alopecia and lichen planopilaris.
research P151 A multicentre real-world evaluation of ritlecitinib in severe alopecia areata: patient-reported outcome measures
Ritlecitinib shows promise in improving severe alopecia areata, with 27% of patients seeing success.
research Depression risk of 5-alpha reductase inhibitors: impact of active-comparator versus non-drug user control groups on risk measurement
5-alpha reductase inhibitors slightly increase depression risk, but the risk varies based on the control group used.
research Development and Characterization of In Situ Gelling Nasal Cilostazol Spanlastics
The developed nasal gel improves cilostazol delivery to the brain, enhancing its effectiveness and reducing side effects.
research 865 Frontal fibrosing alopecia is associated with dysregulation of cholesterol biosynthesis pathways, fibrosis and mast cells
Frontal Fibrosing Alopecia involves disrupted cholesterol pathways, fibrosis, and increased mast cells.
research Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review
5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.
research PO:17:252 | The choice between belimumab and anifrolumab: analysis of a monocentric cohort
The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.
research New drugs: Agalsidase alfa
Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.